Article

Wavefront-guided enhancement of highly aberrated eyes safe, predictable in study

Lisbon, Portugal - Preliminary data have demonstrated that VISX CustomVue wavefront-guided enhancement of eyes with high aberrations after a previous refractive surgery is safe and effective. Edward Manche, MD, described the retrospective analysis of 120 eyes of 102 patients Tuesday at the European Society of Cataract and Refractive Surgeons meeting.

Lisbon, Portugal - Preliminary data have demonstrated that VISX CustomVue wavefront-guided enhancement of eyes with high aberrations after a previous refractive surgery is safe and effective. Edward Manche, MD, described the retrospective analysis of 120 eyes of 102 patients Tuesday at the European Society of Cataract and Refractive Surgeons meeting.

One hundred nineteen eyes had undergone LASIK and one eye had undergone PRK. The preoperative spherical equivalent refractions ranged from –1.25 to 7 D. Eighty-four of the eyes reached the 3-month time point after the enhancement procedure.

Dr. Manche, who is from Stanford University School of Medicine, Stanford, CA, United States, reported that 3 months postoperatively, the mean spherical equivalent before the enhancement procedure was –1.12 D and decreased to –0.22 D (range, –0.75 to 0.75 D); 95% of the eyes were within 0.05 D of emmetropia and all patients were within 0.75 D of emmetropia. At the 3-month examination, 99% of eyes had an uncorrected visual acuity (UCVA) of 20/20 and 72% had an UCVA of 20/15. Wavefront analysis showed that the mean total higher-order root mean square error decreased from 0.40 µm preoperatively to 0.34 µm postoperatively by the 3-month examination.

“These preliminary data show that the VISX CustomVue wavefront-guided enhancement surgery is effective, safe, and predictable in highly aberrated eyes,” Dr. Manche stated.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.